Agile Therapeutics Stock Price, News & Analysis (NASDAQ:AGRX)

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AGRX shares.
View AGRX analyst ratings or view top-rated stocks.

2 Wall Street analysts have issued 12 month price objectives for Agile Therapeutics' shares. Their AGRX share price targets range from $5.00 to $12.00. On average, they predict the company's share price to reach $8.50 in the next twelve months. This suggests a possible upside of 302.9% from the stock's current price.
View analysts price targets for AGRX or view top-rated stocks among Wall Street analysts.

Agile Therapeutics' stock was trading at $0.2270 at the start of the year. Since then, AGRX stock has increased by 829.5% and is now trading at $2.1099.
View the best growth stocks for 2023 here.

Agile Therapeutics saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 18,000 shares, an increase of 12.5% from the October 31st total of 16,000 shares. Based on an average daily trading volume, of 40,600 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.8% of the shares of the company are short sold.
View Agile Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024.
View our AGRX earnings forecast.

Agile Therapeutics, Inc. (NASDAQ:AGRX) issued its earnings results on Tuesday, November, 2nd. The specialty pharmaceutical company reported ($7.20) EPS for the quarter, topping analysts' consensus estimates of ($7.60) by $0.40. The specialty pharmaceutical company earned $1.29 million during the quarter, compared to analyst estimates of $1.49 million. During the same quarter in the previous year, the business posted ($7.20) EPS.

Agile Therapeutics's stock reverse split before market open on Wednesday, April 27th 2022. The 1-40 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Agile Therapeutics updated its FY 2023 earnings guidance on Thursday, November, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $25.00M-, compared to the consensus revenue estimate of $21.66 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Agile Therapeutics investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Nabriva Therapeutics (NBRV), AcelRx Pharmaceuticals (ACRX), Micron Technology (MU) and Novavax (NVAX).

Agile Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (5.08%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Alfred Altomari, Dennis Reilly, Jason Butch and Perceptive Advisors Llc.
View institutional ownership trends.

Shares of AGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.